Proton Pump Inhibitors and H2 Blockers

Gastric Acid Secretion Physiology

• Mechanism of PPI Action: PPIs are prodrugs (weak bases) that must be activated in the acidic environment of the parietal cell canaliculus. After oral administration and absorption in the small intestine, PPIs accumulate in the acidic secretory canaliculi where they are protonated and converted to their active sulfenamide form. This activated form forms irreversible disulfide bonds with cysteine residues on the H+/K+-ATPase pump, covalently inhibiting this enzyme. Because PPIs work only when the pump is actively secreting (state-dependent inhibition), they achieve maximal effect after 3-5 days of daily dosing as new pump molecules are synthesized. A single dose may inhibit only 50-70% of acid secretion, but continued daily dosing achieves >90% suppression because the pump has a slow turnover rate (half-life ~60 hours). Restoration of acid secretion requires de novo synthesis of H+/K+-ATPase protein, explaining why acid rebound hypersecretion may occur 1-2 weeks after PPI discontinuation.

• Mechanism of H2 Blocker Action: H2 blockers competitively antagonize histamine at the H2 receptor on parietal cells, blocking the final common pathway of acid secretion regardless of other stimuli. This mechanism results in reversible inhibition—acid secretion resumes when the drug dissociates from the receptor. H2 blockers achieve approximately 70% acid suppression and are less effective than PPIs because they do not address gastrin- and acetylcholine-mediated acid stimulation; gastrin-stimulated acid secretion may overcome H2 blockade in some patients. The onset of action is faster (30-60 minutes) compared to PPIs (requiring 24-48 hours for maximal effect), making H2 blockers useful for acute symptom relief.

• Acid-Related Disease Pathogenesis: Peptic ulcer disease develops when gastric acid overwhelms mucosal defense mechanisms. The gastric mucosa normally resists acid injury through multiple protective mechanisms: a mucus layer (2-3 mm thick) containing bicarbonate, tight epithelial junctions, rapid epithelial cell renewal (every 3-5 days), and prostaglandin-mediated cytoprotection. Helicobacter pylori infection disrupts these defenses through chronic inflammation and direct epithelial damage; non-steroidal anti-inflammatory drugs (NSAIDs) inhibit cytoprotective prostaglandins and directly injure mucosa. Zollinger-Ellison syndrome (gastrin-secreting neuroendocrine tumors) bypasses normal feedback inhibition of gastrin, causing acid hypersecretion. In gastroesophageal reflux disease (GERD), acid suppression reduces esophageal mucosal injury from refluxed gastric contents. Acid suppression shifts the gastric microbiota composition and may permit colonization by pathogenic bacteria, a concern with prolonged PPI use.

• Helicobacter pylori Infection: This microaerophilic bacterium colonizes the gastric mucosa in approximately 50% of the world's population, with higher prevalence in developing countries, lower socioeconomic groups, and those with crowded living conditions. H. pylori causes chronic inflammation leading to peptic ulcer disease in 10-15% of infected individuals over a lifetime and is a proven risk factor for gastric adenocarcinoma and MALT lymphoma. The infection upregulates gastrin secretion, promoting acid hypersecretion that paradoxically worsens mucosal damage.

• NSAID Use: Approximately 30% of chronic NSAID users develop peptic ulcer disease. NSAIDs inhibit cyclooxygenase-1 (COX-1), reducing prostaglandin E2 production critical for mucosal defense, and directly injure the epithelium. Acetylsalicylic acid has the highest ulcerogenic potential. Risk increases significantly with age >65 years, concurrent corticosteroid use, H. pylori co-infection, previous ulcer history, and high NSAID doses.

• Gastroesophageal Reflux Disease (GERD): This results from either excessive acid secretion or, more commonly, inadequate lower esophageal sphincter (LES) function with transient LES relaxations allowing reflux. Risk factors include obesity, pregnancy, chocolate/caffeine/alcohol consumption, smoking, and supine positioning. Chronic acid exposure to stratified squamous epithelium causes heartburn, regurgitation, and potential progression to Barrett's esophagus (intestinal metaplasia conferring increased adenocarcinoma risk).

• Zollinger-Ellison Syndrome: Rare gastrin-secreting neuroendocrine tumors (gastrinomas) cause severe peptic ulcer disease and chronic diarrhea. Approximately 60-90% are malignant, and 20-30% are associated with MEN-1 syndrome. Markedly elevated fasting gastrin levels (>1000 pg/mL) and low gastric pH (<2) are diagnostic.

• Stress Ulcers: Acute ulceration in critically ill patients results from mucosal ischemia, reduced mucus/bicarbonate secretion, and acid-induced injury in the setting of severe systemic illness, major surgery, burns, sepsis, or mechanical ventilation. Stress ulcer prophylaxis with acid suppressants is standard in ICU patients.

• Medication-Related: Beyond NSAIDs, bisphosphonates can cause severe esophageal injury if not taken properly, and aspirin in high doses increases ulcer risk.

PPIs and H2 Blockers—Therapeutic Indications and Clinical Context

• Peptic Ulcer Disease Symptoms (indication for therapy): Epigastric pain, typically sharp or burning, worse on an empty stomach and improved by antacids or food. NSAIDs present with ulcer pain often in the elderly without classic heartburn. H. pylori ulcers may present with severe abdominal pain. Physical exam is usually unremarkable unless perforation has occurred (acute abdomen with peritoneal signs).

• GERD Symptoms (indication for therapy): Heartburn (retrosternal burning), regurgitation (return of food/fluid to mouth without retching), dysphagia (if stricture develops), chest pain mimicking angina, chronic cough, hoarseness, and laryngitis from nocturnal reflux. Alarm symptoms requiring urgent evaluation include dysphagia, odynophagia, weight loss, anemia, and hematemesis—these suggest complicated disease or malignancy.

• Erosive Esophagitis Findings: On endoscopy, mucosal breaks with hyperemia, visible fibrin, and potential ulceration define erosive disease requiring more intensive acid suppression.

• Barrett's Esophagus: Long-standing GERD causes replacement of normal squamous epithelium with columnar epithelium, visualized as salmon-colored mucosa above the gastroesophageal junction, with dysplasia risk requiring surveillance endoscopy.

• Zollinger-Ellison Syndrome Presentation: Severe, refractory peptic ulcer disease, often multiple ulcers in unusual locations (distal duodenum or jejunum), with chronic secretory diarrhea (40% of patients), and weight loss. Family history of MEN-1 or pituitary/parathyroid tumors is relevant.

• Stress Ulcer Prophylaxis Context: Critically ill patients without preceding symptoms but at high risk for acute ulceration due to physiologic stress.

Diagnostic Evaluation of Acid-Related Disorders (Not the Drugs Themselves)

• Clinical Suspicion for Peptic Ulcer Disease: Begin with history characterizing pain (epigastric, relationship to meals, alleviating factors) and identification of risk factors (NSAID use, H. pylori exposure, previous ulcer). Alarm features (weight loss, dysphagia, hematemesis, melena) suggest complicated disease requiring endoscopy.

• H. pylori Testing: Diagnosis confirmation is essential before treatment. Non-invasive tests include: Urea breath test (gold standard; sensitivity/specificity >95%), stool antigen test (fecal immunoassay; ~90% sensitivity/specificity), and serology (detects antibodies but cannot distinguish current from past infection). Invasive testing includes endoscopic biopsy with rapid urease test (CLO test; sensitivity ~95% in untreated infection) or histopathology. Critical point: Discontinue PPIs 2 weeks before testing and bismuth/antibiotics 4 weeks before, as these may suppress H. pylori and cause false negatives.

• Fasting Gastric pH Measurement: In suspected Zollinger-Ellison syndrome, gastric pH <2 on aspiration is consistent with significant acid production. Normal fasting pH is 1.0-3.0.

• Fasting Serum Gastrin Concentration: In Zollinger-Ellison syndrome, fasting gastrin >1000 pg/mL is virtually diagnostic (normal <100 pg/mL). Values 100-1000 pg/mL require secretin stimulation test: a paradoxical increase in gastrin >200 pg/mL above baseline confirms gastrinoma (normal individuals suppress gastrin with secretin).

• Endoscopic Evaluation: Upper endoscopy directly visualizes mucosal lesions. For peptic ulcer disease, endoscopy identifies ulcer size, location, and depth; allows assessment of H. pylori status via biopsy; and enables therapeutic intervention (hemostasis). For GERD, endoscopy evaluates esophageal damage severity (LA classification: Grade A to D), Barrett's metaplasia extent, and dysplasia on biopsy.

• Diagnostic Criteria for GERD: Based on symptom frequency (≥2 days/week for 2 weeks) or LA endoscopic classification in erosive disease. The Montreal definition includes typical symptoms (heartburn, regurgitation) and atypical presentations (cough, hoarseness).

• Differential Diagnosis Considerations: Acute coronary syndrome may mimic GERD chest pain—obtain electrocardiogram and cardiac biomarkers. Peptic ulcer must be distinguished from gastric cancer (endoscopic biopsies in gastric ulcers are mandatory). Medication-induced esophageal injury (bisphosphonates, potassium chloride) presents similarly to reflux but requires specific positional precautions.

Proton Pump Inhibitors

• First-Line Agents and Mechanism: Omeprazole (Prilosec) 20 mg daily is the prototypical PPI and is often used as the standard. Other commonly prescribed PPIs include lansoprazole (Prevacid) 30 mg daily, pantoprazole (Protonix) 40 mg daily, esomeprazole (Nexium) 20-40 mg daily (the S-enantiomer of omeprazole with slightly faster metabolism), and rabeprazole (AcipHex) 20 mg daily. All are equally efficacious at standard doses; choice depends on insurance coverage, patient tolerance, and specific formulation advantages (pantoprazole available in IV form for hospitalized patients). Mechanism: Irreversible H+/K+-ATPase inhibition achieves >90% acid suppression. PPIs are given 30-60 minutes before meals on an empty stomach to allow proper activation in the acidic canalicular environment.

• Dosing Context: Standard dose PPIs achieve remission of duodenal ulcers in >95% of patients within 4 weeks and gastric ulcers in >90% within 8 weeks. For GERD, once-daily dosing maintains remission in 80-90% of patients; refractory GERD may require twice-daily dosing (e.g., omeprazole 20 mg twice daily). In Zollinger-Ellison syndrome, high-dose PPIs are required, often starting at 60 mg daily, with dose titration based on gastric pH (target pH >4).

• Duration of Therapy: For peptic ulcer disease, 4-8 weeks of PPI monotherapy is standard; however, eradication of H. pylori (if present) is the critical step preventing recurrence. For GERD, many patients require long-term maintenance therapy; intermittent or on-demand dosing (7 days per month) may be acceptable for mild disease. For stress ulcer prophylaxis in ICU patients, continue during critical illness and taper after discharge.

H2-Receptor Antagonists

• Common H2 Blockers: Famotidine (Pepcid) is the most commonly prescribed, given 20 mg twice daily or 40 mg once at bedtime (half-life ~3 hours requires twice-daily dosing for optimal effect). Ranitidine (now withdrawn from U.S. market due to NDMA contamination) was formerly standard. Cimetidine 300 mg four times daily is older, less selective (inhibits cytochrome P450), and now rarely used. Nizatidine 150 mg twice daily is an alternative.

• Mechanism and Efficacy: H2 blockers competitively block histamine at the H2 receptor, achieving ~70% acid suppression. Onset of action is faster (30-60 minutes) than PPIs, making them suitable for rapid symptom relief. Tolerance develops in some patients (reduced effectiveness over 1-2 weeks of continuous use), limiting their long-term utility for moderate-severe disease.

• Preferred Situations: H2 blockers remain appropriate for mild, intermittent heartburn, stress ulcer prophylaxis in hospitalized patients (often used empirically in the ICU in conjunction with or instead of PPIs), and patients unable to take PPIs. Cost is substantially lower than PPIs. They are safe in pregnancy (FDA Category B).

H. pylori Eradication Regimens

• Triple Therapy (Traditional First-Line): PPI (omeprazole 20 mg twice daily, or equivalent) + amoxicillin 1 g twice daily + clarithromycin 500 mg twice daily for 10-14 days. Eradication rates are 85-95% depending on clarithromycin resistance. This is the most commonly tested regimen.

• Quadruple Therapy (PPI-Based): PPI + bismuth subsalicylate 525 mg four times daily + tetracycline 500 mg four times daily + metronidazole 500 mg three times daily for 10-14 days. Used in clarithromycin-resistant strains (prevalence 10-40% depending on geography).

• Alternative: Bismuth Quadruple Therapy (Non-PPI): Bism

Class effects of profound acid suppression (PPIs)

• Hypomagnesemia: the subject of an FDA safety communication; presumed impaired intestinal TRPM6/7-mediated Mg absorption. Presents after months-to-years of use with refractory hypocalcemia and hypokalemia (Mg is required for PTH release and for ROMK function), tetany, seizures, or arrhythmia. Check a magnesium level in long-term users and before starting drugs like digoxin or diuretics; treatment is repletion plus drug withdrawal, not a specific antidote.
• Vitamin B12 and iron malabsorption: gastric acid and pepsin liberate B12 from dietary protein, and acid reduces Fe³⁺ to absorbable Fe²⁺. Long-term use can produce megaloblastic anemia or iron-deficiency anemia.
• Enteric infection: FDA warns of increased *Clostridioides difficile*-associated diarrhea; loss of the gastric acid barrier also raises risk of Salmonella/Campylobacter and is associated with community-acquired pneumonia and, in cirrhosis, spontaneous bacterial peritonitis.
• Acute interstitial nephritis: idiosyncratic, non-dose-related hypersensitivity — rising creatinine, sterile pyuria, WBC casts, eosinophiluria, sometimes rash and fever. The intervention is prompt drug discontinuation; corticosteroids are used for persistent injury.
• Hypergastrinemia: loss of acid feedback raises gastrin, causing ECL-cell hyperplasia, fundic gland polyps (benign), and rebound acid hypersecretion on abrupt withdrawal — taper rather than stop abruptly. The gastric carcinoid seen in rats has not been demonstrated in humans.
• Osteoporotic fracture: FDA labeling notes an association with hip, wrist, and spine fractures at high dose or prolonged duration.

Drug interactions and contraindications

• CYP2C19 inhibition: omeprazole/esomeprazole blunt conversion of clopidogrel to its active metabolite; FDA advises avoiding this combination — pantoprazole is the preferred PPI. PPIs also raise methotrexate levels.
• pH-dependent absorption: PPIs markedly reduce absorption of atazanavir, rilpivirine, ketoconazole/itraconazole capsules, and cefuroxime axetil; co-administration is contraindicated or discouraged.

H2 blockers

• Cimetidine: potent CYP450 inhibitor (warfarin, phenytoin, theophylline) and antiandrogen — gynecomastia, impotence, galactorrhea; also CNS confusion in elderly or renally impaired patients.
• Famotidine/nizatidine: renally cleared, requiring dose reduction in CKD; headache and delirium are the usual complaints. Ranitidine was withdrawn from the U.S. market for NDMA contamination.

• Hold the PPI before H. pylori testing: PPIs suppress H. pylori density and urease activity, causing false-negative urea breath and stool antigen tests. Stop the PPI 2 weeks (and bismuth/antibiotics 4 weeks) before testing; serology is unaffected by PPIs but is not recommended for diagnosing active infection or confirming eradication — the preferred approach is to hold the PPI and use urea breath or stool antigen testing.
• Cimetidine is the antiandrogen: a stem describing gynecomastia, impotence, or galactorrhea in a man treated for reflux, or an unexpectedly elevated INR/phenytoin level, points to cimetidine's androgen-receptor blockade and CYP450 inhibition. Famotidine is the distractor-free substitute — it does neither.
• Pick pantoprazole with clopidogrel: omeprazole and esomeprazole inhibit CYP2C19 and blunt clopidogrel activation (FDA warning). Pantoprazole is the board answer after coronary stenting.
• Refractory hypocalcemia + hypokalemia on a chronic PPI = hypomagnesemia: repleting calcium or potassium alone fails until magnesium is replaced and the PPI is stopped. Magnesium is required for PTH secretion and ROMK channel function.
• Rising creatinine with sterile pyuria and eosinophiluria weeks after starting a PPI is acute interstitial nephritis; the single best next step is stopping the drug, not adding fluids or imaging.
• Timing matters: PPIs are prodrugs activated only in actively secreting canaliculi, so they must be given 30–60 minutes before a meal; maximal effect takes several days. A stem where a patient "takes omeprazole at bedtime with no benefit" is testing dosing timing, not treatment failure.
• Gastric ulcers require biopsy at index endoscopy to exclude malignancy; duodenal ulcers essentially never harbor cancer. Repeat endoscopy at 8–12 weeks is reserved for ulcers that were inadequately biopsied, appear suspicious, are giant, or when symptoms persist. Symptom relief on a PPI does not exclude gastric cancer.
• Common distractors: fundic gland polyps on surveillance endoscopy in a chronic PPI user are benign and need no resection; and the rodent ECL-cell carcinoid finding has not translated to humans. For NSAID ulcer prophylaxis in a woman who could become pregnant, choose a PPI — misoprostol is an abortifacient and contraindicated in pregnancy.